EcoDrugPlus

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSAOCG00000000881
Gene Symbol: LOC111568184
3 Cross references
171 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSAOCG00000002143
Gene Symbol: LOC111566530
3 Cross references
203 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSAOCG00000011196
Gene Symbol: LOC111573489
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSAOCG00000009449
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSAOCG00000012040
Gene Symbol: PTGIR
3 Cross references
188 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSAOCG00000019827
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSAOCG00000017781
Gene Symbol: PTGS1
3 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSAOCG00000006921
Gene Symbol: PTGS2
3 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSAOCG00000017264
Gene Symbol: PSMA1
3 Cross references
271 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSAOCG00000009723
Gene Symbol: PSMA2
3 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSAOCG00000004830
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSAOCG00000003905
Gene Symbol: PSMA4
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).